biostudies-literatureUnknown104(9)Reeves JMSydney Local Health District<h4>Objective</h4>COVID-19 has led to significant morbidity and mortality globally. Post-COVID sequelae can persist beyond the acute and subacute phases of infection, often termed post-COVID syndrome (PCS). There is limited evidence on the appropriate rehabilitation for people with PCS. The aim of this study is to evaluate the effect on exercise capacity, symptoms, cognition, anxiety, depression, health-related quality of life, and fatigue of a 4-week, twice-weekly supervised pulmonary telerehabilitation program compared with usual medical care for people with PCS with persistent respiratory symptoms.<h4>Methods</h4>The study will be a multi-site randomized controlled trial with assessor blinding. Participants with confirmed previous COVID-19 infection and persistent respiratory symptoms wPhysical therapypzae080https://www.ebi.ac.uk/biostudies/studies/S-EPMC11443032biostudies-literatureEffect of a 4-Week Telerehabilitation Program for People With Post-COVID Syndrome on Physical Function and Symptoms: Protocol for a Randomized Controlled Trial.PMC11443032Spencer LMCorte TJReeves JMHan YBarton CLeung RWMBishop JATroy LKTeoh AKYTsai LLJones LBaillie AJAlison JAPeters MfalseEffect of a 4-Week Telerehabilitation Program for People With Post-COVID Syndrome on Physical Function and Symptoms: Protocol for a Randomized Controlled Trial.<h4>Objective</h4>COVID-19 has led to significant morbidity and mortality globally. Post-COVID sequelae can persist beyond the acute and subacute phases of infection, often termed post-COVID syndrome (PCS). There is limited evidence on the appropriate rehabilitation for people with PCS. The aim of this study is to evaluate the effect on exercise capacity, symptoms, cognition, anxiety, depression, health-related quality of life, and fatigue of a 4-week, twice-weekly supervised pulmonary telerehabilitation program compared with usual medical care for people with PCS with persistent respiratory symptoms.<h4>Methods</h4>The study will be a multi-site randomized controlled trial with assessor blinding. Participants with confirmed previous COVID-19 infection and persistent respiratory symptoms w2024-01-01T00:00:00Z2024 Sep2025-04-26T10:25:13.845Z2025-04-06T13:21:04.39ZS-EPMC114430323894336010.1093/ptj/pzae080